Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
Intensification therapy adding a boosted protease inhibitor (PI) to a failing regimen has the potential to worsen the resistance profile. Sixty-six patients included in four different boosted PI intensification studies were assessed and resistance mutations in the reverse transcriptase and protease genes were evaluated at baseline and 4 weeks after the initiation of the intensification strategy. Only one of the 66 patients developed changes in their pattern of mutations able to generate or increase resistance to new drugs.
Blanco
José L
JL
Infectious Diseases Service, IDIBAPS, Hospital Clínic, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Biglia
M Alejandra
MA
Arnedo
Mireia
M
Martínez
Esteban
E
Mallolas
Josep
J
Milinkovic
Ana
A
Laguno
Montserrat
M
Larrousse
Maria
M
Leon
Agathe
A
Lonca
Montserrat
M
García
Felipe
F
Miró
José M
JM
Pumarola
Tomás
T
Gatell
José M
JM
D023241:Antiretroviral Therapy, Highly Active; D002219:Carbamates; D024921:Drug Resistance, Multiple, Viral; D005500:Follow-Up Studies; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D061466:Lopinavir; D009154:Mutation; D011744:Pyrimidinones / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D017211:Treatment Failure; D019562:Viral Load
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; C095108:amprenavir; D019469:Indinavir; D054303:HIV Reverse Transcriptase; D016333:HIV Protease; D019258:Saquinavir; D019438:Ritonavir